NuCana PLC (NCNA) - Total Liabilities
Based on the latest financial reports, NuCana PLC (NCNA) has total liabilities worth $5.50 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NuCana PLC (NCNA) asset resilience to evaluate the company's liquid asset resilience ratio.
NuCana PLC - Total Liabilities Trend (2014–2025)
This chart illustrates how NuCana PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NuCana PLC balance sheet assets.
NuCana PLC Competitors by Total Liabilities
The table below lists competitors of NuCana PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020
|
Germany | €4.83 Million |
|
TOP Ships Inc.
NYSE MKT:TOPS
|
USA | $244.42 Million |
|
Methanor
PA:ALMET
|
France | €43.46K |
|
MEKICS Co Ltd
KQ:058110
|
Korea | ₩19.37 Billion |
|
Cahaya Bintang Medan Tbk Pt
JK:CBMF
|
Indonesia | Rp117.80 Billion |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$389.17K |
|
COLLPLANT BIOTECH. IS-01
F:CPT
|
Germany | €4.30 Million |
|
Anglo Asian Mining Plc
LSE:AAZ
|
UK | GBX84.38 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down NuCana PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NuCana PLC balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NuCana PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NuCana PLC (2014–2025)
The table below shows the annual total liabilities of NuCana PLC from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.50 Million | -37.67% |
| 2024-12-31 | $8.82 Million | -31.75% |
| 2023-12-31 | $12.92 Million | -34.57% |
| 2022-12-31 | $19.75 Million | +65.62% |
| 2021-12-31 | $11.93 Million | +39.29% |
| 2020-12-31 | $8.56 Million | +26.92% |
| 2019-12-31 | $6.75 Million | +20.66% |
| 2018-12-31 | $5.59 Million | +90.49% |
| 2017-12-31 | $2.94 Million | +48.76% |
| 2016-12-31 | $1.97 Million | +14.38% |
| 2015-12-31 | $1.73 Million | +147631.36% |
| 2014-12-31 | $1.17K | -- |
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metab… Read more